Make Informed Investment Decisions with Affordable Access to Experts
Discussing the ORION-1 data recently presented at the 2017 American College of Cardiology Conference.Ticker(s): MDCO, AMGN, REGN, ALNY, SNY
Name: Dr Kausik Kumar Ray - MD
Institution: Imperial College London
- Professor of Public Health, Department of Public Health and Primary Care, School of Public Health, Imperial College London.
- PI for ORION 1 trial assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
- Has been the national lead investigator (SC or EC member) for several major medical trials, and is currently involved in 8 ongoing trials in lipids and diabetes.
Please describe your clinical practice and how many patients you treat.Added By: joe_mccann
What was your reaction to the FOURIER data?Added By: joe_mccann
Do you think each PCSK9 drug will need specific outcomes results?Added By: joe_mccann
Do the FOURIER results change the "expected" benefits from various LDL lowering changes?Added By: joe_mccann
How does the inclusion criteria in ORION-1 trial compare to ODYSSEY and FOURIER. Is 130mg/dL better in your opinion for these trials? Were enough patients on optimal statin regimens such as Ezetimibe
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.